{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T18:52:25Z","timestamp":1762023145235,"version":"build-2065373602"},"publisher-location":"Cham","reference-count":138,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030345204"},{"type":"electronic","value":"9783030345211"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-34521-1_15","type":"book-chapter","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T08:05:40Z","timestamp":1586419540000},"page":"405-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Heparanase: A Potential Therapeutic Target in Sarcomas"],"prefix":"10.1007","author":[{"given":"Giuliana","family":"Cassinelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Lanzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,10]]},"reference":[{"volume-title":"WHO classification of tumours of soft tissue and bone, 4th edn IARC WHO classification of tumours, no 5","year":"2013","key":"15_CR1","unstructured":"Fletcher, C. D. M., Bridge, J. A., Hogendoorn, P. C. W., et al. (Eds.). (2013). WHO classification of tumours of soft tissue and bone, 4th edn IARC WHO classification of tumours, no 5. Geneva: WHO Press."},{"issue":"8","key":"15_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrc3087","volume":"11","author":"BS Taylor","year":"2011","unstructured":"Taylor, B. S., Barretina, J., Maki, R. G., et al. (2011). Advances in sarcoma genomics and new therapeutic targets. Nature Reviews. Cancer, 11(8), 541\u2013557.","journal-title":"Nature Reviews. Cancer"},{"issue":"8","key":"15_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/ng.619","volume":"42","author":"J Barretina","year":"2010","unstructured":"Barretina, J., Taylor, B. S., Banerji, S., et al. (2010). Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics, 42(8), 715\u2013721.","journal-title":"Nature Genetics"},{"issue":"10","key":"15_CR4","first-page":"2572","volume":"30","author":"G Bonadonna","year":"1970","unstructured":"Bonadonna, G., Monfardini, S., De Lena, M., et al. (1970). Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Research, 30(10), 2572\u20132582.","journal-title":"Cancer Research"},{"issue":"1","key":"15_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0872-y","volume":"15","author":"AM Frezza","year":"2017","unstructured":"Frezza, A. M., Stacchiotti, S., & Gronchi, A. (2017). Systemic treatment in advanced soft tissue sarcoma: What is standard, what is new. BMC Medicine, 15(1), 109.","journal-title":"BMC Medicine"},{"issue":"10s","key":"15_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2217\/fon-2018-0074","volume":"14","author":"JY Blay","year":"2018","unstructured":"Blay, J. Y. (2018). Getting up-to-date in the management of soft tissue sarcoma. Future Oncology, 14(10s), 3\u201313.","journal-title":"Future Oncology"},{"issue":"12","key":"15_CR7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/14737140.2017.1390431","volume":"17","author":"H Kose\u0142a-Paterczyk","year":"2017","unstructured":"Kose\u0142a-Paterczyk, H., & Rutkowski, P. (2017). Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas. Expert Review of Anticancer Therapy, 17(12), 1107\u20131116.","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"6","key":"15_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1586\/14737140.2014.885840","volume":"14","author":"S Radaelli","year":"2014","unstructured":"Radaelli, S., Stacchiotti, S., Casali, P. G., et al. (2014). Emerging therapies for adult soft tissue sarcoma. Expert Review of Anticancer Therapy, 14(6), 689\u2013704.","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"4","key":"15_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nrclinonc.2014.26","volume":"11","author":"M Linch","year":"2014","unstructured":"Linch, M., Miah, A. B., Thway, K., et al. (2014). Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nature Reviews. Clinical Oncology, 11(4), 187\u2013202.","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"15_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2017.10.020","volume":"88","author":"M Vos","year":"2018","unstructured":"Vos, M., & Sleijfer, S. (2018). EJC\u2019s biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives. European Journal of Cancer, 88, 87\u201391.","journal-title":"European Journal of Cancer"},{"issue":"2","key":"15_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JCO.2017.75.1610","volume":"36","author":"SM Pollack","year":"2018","unstructured":"Pollack, S. M., Ingham, M., & Spraker, M. B. (2018). Emerging targeted and immune-based therapies in sarcoma. The Journal of Clinical Oncology, 36(2), 125\u2013135.","journal-title":"The Journal of Clinical Oncology"},{"issue":"14","key":"15_CR12","doi-asserted-by":"publisher","first-page":"12234","DOI":"10.18632\/oncotarget.3498","volume":"6","author":"S Movva","year":"2015","unstructured":"Movva, S., Wen, W., & al, C. W. (2015). Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets. Oncotarget, 6(14), 12234\u201312247.","journal-title":"Oncotarget"},{"key":"15_CR13","doi-asserted-by":"crossref","unstructured":"Perry JA, Kiezun A, Tonzi P et al. (2014) Complementary genomic approaches highlight the PI3K\/mTOR pathway as a common vulnerability in osteosarcoma. Proceedings of the National Academy of Sciences of the United States of America 111(51):E5564\u2013E5573.","DOI":"10.1073\/pnas.1419260111"},{"key":"15_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15936","volume":"8","author":"S Behjati","year":"2017","unstructured":"Behjati, S., Tarpey, P. S., Haase, K., et al. (2017). Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nature Communications, 8, 15936.","journal-title":"Nature Communications"},{"issue":"5","key":"15_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cancergen.2016.03.004","volume":"209","author":"P Hingorani","year":"2016","unstructured":"Hingorani, P., Janeway, K., Crompton, B. D., et al. (2016). Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genetics, 209(5), 182\u2013194.","journal-title":"Cancer Genetics"},{"issue":"10","key":"15_CR16","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1001\/jamaoncol.2018.0723","volume":"4","author":"C Lucchesi","year":"2018","unstructured":"Lucchesi, C., Khalifa, E., Laizet, Y., et al. (2018). Targetable alterations in adult patients with soft-tissue sarcomas: Insights for personalized therapy. JAMA Oncology, 4(10), 1398\u20131404.","journal-title":"JAMA Oncology"},{"key":"15_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fonc.2015.00248","volume":"5","author":"M Ehnman","year":"2015","unstructured":"Ehnman, M., & Larsson, O. (2015). Microenvironmental targets in sarcoma. Frontiers in Oncology, 5, 248.","journal-title":"Frontiers in Oncology"},{"issue":"2","key":"15_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.critrevonc.2014.02.001","volume":"91","author":"YM Versleijen-Jonkers","year":"2014","unstructured":"Versleijen-Jonkers, Y. M., Vlenterie, M., van de Luijtgaarden, A. C., et al. (2014). Anti-angiogenic therapy, a new player in the field of sarcoma treatment. Critical Reviews in Oncology\/Hematology, 91(2), 172\u2013185.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"6","key":"15_CR19","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20140075","volume":"34","author":"L Rocchi","year":"2014","unstructured":"Rocchi, L., Caraffi, S., Perris, R., et al. (2014). The angiogenic asset of soft tissue sarcomas: A new tool to discover new therapeutic targets. Bioscience Reports, 34(6), e00147.","journal-title":"Bioscience Reports"},{"issue":"6","key":"15_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00428-006-0304-4","volume":"449","author":"K Shintani","year":"2006","unstructured":"Shintani, K., Matsumine, A., Kusuzaki, K., et al. (2006). Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas. Virchows Archiv, 449(6), 673\u2013681.","journal-title":"Virchows Archiv"},{"issue":"21","key":"15_CR21","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1002\/cncr.26116","volume":"117","author":"J Yang","year":"2011","unstructured":"Yang, J., Yang, D., Sun, Y., et al. (2011). Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer, 117(21), 4925\u20134938.","journal-title":"Cancer"},{"issue":"11","key":"15_CR22","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s00264-012-1629-z","volume":"36","author":"J Lammli","year":"2012","unstructured":"Lammli, J., Fan, M., Rosenthal, H. G., et al. (2012). Expression of vascular endothelial growth factor correlates with the advance of clinical osteosarcoma. International Orthopaedics, 36(11), 2307\u20132313.","journal-title":"International Orthopaedics"},{"issue":"1","key":"15_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s13277-013-1019-1","volume":"35","author":"XW Yu","year":"2014","unstructured":"Yu, X. W., Wu, T. Y., Yi, X., et al. (2014). Prognostic significance of VEGF expression in osteosarcoma: A meta-analysis. Tumour Biology, 35(1), 155\u2013160.","journal-title":"Tumour Biology"},{"issue":"4","key":"15_CR24","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-03-0038","volume":"10","author":"B Fuchs","year":"2004","unstructured":"Fuchs, B., Inwards, C. Y., & Janknecht, R. (2004). Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing\u2019s sarcoma. Clinical Cancer Research, 10(4), 1344\u20131353.","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"15_CR25","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/sj.onc.1204133","volume":"20","author":"JP Zwerner","year":"2001","unstructured":"Zwerner, J. P., & May, W. A. (2001). PDGF-C is an EWS\/FLI induced transforming growth factor in Ewing family tumors. Oncogene, 20(5), 626\u2013633.","journal-title":"Oncogene"},{"issue":"8","key":"15_CR26","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1158\/0008-5472.CAN-08-3807","volume":"69","author":"C M\u00e9nard","year":"2009","unstructured":"M\u00e9nard, C., Blay, J. Y., Borg, C., et al. (2009). Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Research, 69(8), 3563\u20133569.","journal-title":"Cancer Research"},{"issue":"2","key":"15_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","volume":"23","author":"G Germano","year":"2013","unstructured":"Germano, G., Frapolli, R., Belgiovine, C., et al. (2013). Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell, 23(2), 249\u2013262.","journal-title":"Cancer Cell"},{"issue":"17","key":"15_CR28","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1002\/cncr.30726","volume":"123","author":"SM Pollack","year":"2017","unstructured":"Pollack, S. M., He, Q., Yearley, J. H., et al. (2017). T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer, 123(17), 3291\u20133304.","journal-title":"Cancer"},{"issue":"4","key":"15_CR29","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","volume":"171","author":"Cancer Genome Atlas Research Network","year":"2017","unstructured":"Cancer Genome Atlas Research Network. (2017). Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell, 171(4), 950\u2013965.","journal-title":"Cell"},{"issue":"19","key":"15_CR30","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1002\/cncr.31517","volume":"124","author":"AJ Wisdom","year":"2018","unstructured":"Wisdom, A. J., Mowery, Y. M., Riedel, R. F., et al. (2018). Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. Cancer, 124(19), 3819\u20133829.","journal-title":"Cancer"},{"issue":"8","key":"15_CR31","first-page":"3855","volume":"46","author":"W Ricoveri","year":"1986","unstructured":"Ricoveri, W., & Cappelletti, R. (1986). Heparan sulfate endoglycosidase and metastatic potential in murine fibrosarcoma and melanoma. Cancer Research, 46(8), 3855\u20133861.","journal-title":"Cancer Research"},{"issue":"2","key":"15_CR32","first-page":"417","volume":"77","author":"M Becker","year":"1986","unstructured":"Becker, M., Moczar, M., & al, P. M. F. (1986). Solubilization and degradation of extracellular matrix by various metastatic cell lines derived from a rat rhabdomyosarcoma. Journal of the National Cancer Institute, 77(2), 417\u2013424.","journal-title":"Journal of the National Cancer Institute"},{"issue":"4","key":"15_CR33","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.bbrc.2006.01.048","volume":"341","author":"I Shafat","year":"2006","unstructured":"Shafat, I., Zcharia, E., Nisman, B., et al. (2006). An ELISA method for the detection and quantification of human heparanase. Biochemical and Biophysical Research Communications, 341(4), 958\u2013963.","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"11","key":"15_CR34","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1593\/neo.07673","volume":"9","author":"I Shafat","year":"2007","unstructured":"Shafat, I., Barak, A. B., Postovsky, S., et al. (2007). Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment. Neoplasia, 9(11), 909\u2013916.","journal-title":"Neoplasia"},{"issue":"9","key":"15_CR35","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1111\/j.1582-4934.2010.01190.x","volume":"15","author":"I Shafat","year":"2011","unstructured":"Shafat, I., Ben-Arush, M. W., Issakov, J., et al. (2011). Pre-clinical and clinical significance of heparanase in Ewing\u2019s sarcoma. Journal of Cellular and Molecular Medicine, 15(9), 1857\u20131864.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"15_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-304","volume":"9","author":"V Masola","year":"2009","unstructured":"Masola, V., Maran, C., Tassone, E., et al. (2009). Heparanase activity in alveolar and embryonal rhabdomyosarcoma: Implications for tumor invasion. BMC Cancer, 9, 304.","journal-title":"BMC Cancer"},{"issue":"10","key":"15_CR37","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.bcp.2013.02.023","volume":"85","author":"G Cassinelli","year":"2013","unstructured":"Cassinelli, G., Lanzi, C., Tortoreto, M., et al. (2013). Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochemical Pharmacology, 85(10), 1424\u20131432.","journal-title":"Biochemical Pharmacology"},{"key":"15_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.canlet.2017.12.009","volume":"415","author":"G Cassinelli","year":"2018","unstructured":"Cassinelli, G., Dal Bo, L., Favini, E., et al. (2018). Supersulfated low-molecular-weight heparin synergizes with IGF1R\/IR inhibitor to suppress synovial sarcoma growth and metastases. Cancer Letters, 415, 187\u2013197.","journal-title":"Cancer Letters"},{"key":"15_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1756-9966-33-39","volume":"33","author":"O Kazarin","year":"2014","unstructured":"Kazarin, O., Ilan, N., Naroditzky, I., et al. (2014). Expression of heparanase in soft tissue sarcomas of adults. Journal of Experimental & Clinical Cancer Research, 33, 39.","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"10","key":"15_CR40","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1111\/febs.12168","volume":"280","author":"VC Ramani","year":"2013","unstructured":"Ramani, V. C., Purushothaman, A., Stewart, M. D., et al. (2013). The heparanase\/syndecan-1 axis in cancer: Mechanisms and therapies. The FEBS Journal, 280(10), 2294\u20132306.","journal-title":"The FEBS Journal"},{"issue":"2","key":"15_CR41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.canlet.2016.09.004","volume":"382","author":"G Cassinelli","year":"2016","unstructured":"Cassinelli, G., Zaffaroni, N., & Lanzi, C. (2016). The heparanase\/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomas. Cancer Letter, 382(2), 245\u2013254.","journal-title":"Cancer Letter"},{"issue":"4","key":"15_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/iep.12135","volume":"96","author":"J Gallagher","year":"2015","unstructured":"Gallagher, J. (2015). Fell-Muir lecture: Heparan sulphate and the art of cell regulation: A polymer chain conducts the protein orchestra. International Journal of Experimental Pathology, 96(4), 203\u2013231.","journal-title":"International Journal of Experimental Pathology"},{"issue":"18","key":"15_CR43","doi-asserted-by":"publisher","first-page":"9152","DOI":"10.1021\/acs.chemrev.8b00354","volume":"118","author":"NK Karamanos","year":"2018","unstructured":"Karamanos, N. K., Piperigkou, Z., Theocharis, A. D., et al. (2018). Proteoglycan chemical diversity drives multifunctional cell regulation and therapeutics. Chemical Reviews, 118(18), 9152\u20139232.","journal-title":"Chemical Reviews"},{"issue":"4","key":"15_CR44","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3109\/03008207.2015.1045066","volume":"56","author":"PC Billings","year":"2015","unstructured":"Billings, P. C., & Pacifici, M. (2015). Interactions of signaling proteins, growth factors and other proteins with heparan sulfate: Mechanisms and mysteries. Connective Tissue Research, 56(4), 272\u2013280.","journal-title":"Connective Tissue Research"},{"issue":"6","key":"15_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.tibs.2014.03.001","volume":"39","author":"EH Knelson","year":"2014","unstructured":"Knelson, E. H., Nee, J. C., & Blobe, G. C. (2014). Heparan sulfate signaling in cancer. Trends in Biochemical Sciences, 39(6), 277\u2013288.","journal-title":"Trends in Biochemical Sciences"},{"issue":"26","key":"15_CR46","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.2174\/0929867324666170216114248","volume":"24","author":"C Lanzi","year":"2017","unstructured":"Lanzi, C., Zaffaroni, N., & Cassinelli, G. (2017). Targeting heparan sulfate proteoglycans and their modifying enzymes to enhance anticancer chemotherapy efficacy and overcome drug resistance. Current Medicinal Chemistry, 24(26), 2860\u20132886.","journal-title":"Current Medicinal Chemistry"},{"key":"15_CR47","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3389\/fendo.2018.00483","volume":"9","author":"A Nagarajan","year":"2018","unstructured":"Nagarajan, A., Malvi, P., & Wajapeyee, N. (2018). Heparan sulfate and heparan sulfate proteoglycans in cancer initiation and progression. Front Endocrinol (Lausanne), 9, 483.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"15_CR48","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.matbio.2017.10.008","volume":"75-76","author":"AD Theocharis","year":"2019","unstructured":"Theocharis, A. D., & Karamanos, N. K. (2019). Proteoglycans remodeling in cancer: Underlying molecular mechanisms. Matrix Biology, 75-76, 220\u2013259.","journal-title":"Matrix Biology"},{"issue":"1","key":"15_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1158\/0008-5472.CAN-06-1650","volume":"67","author":"D Williamson","year":"2007","unstructured":"Williamson, D., Selfe, J., Gordon, T., et al. (2007). Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Research, 67(1), 57\u201365.","journal-title":"Cancer Research"},{"issue":"4","key":"15_CR50","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1083\/jcb.201008087","volume":"192","author":"F Li","year":"2011","unstructured":"Li, F., Shi, W., Capurro, M., et al. (2011). Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating hedgehog signaling. The Journal of Cell Biology, 192(4), 691\u2013704.","journal-title":"The Journal of Cell Biology"},{"key":"15_CR51","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.matbio.2013.12.007","volume":"35","author":"J Filmus","year":"2014","unstructured":"Filmus, J., & Capurro, M. (2014). The role of glypicans in hedgehog signaling. Matrix Biology, 35, 248\u2013252.","journal-title":"Matrix Biology"},{"issue":"9","key":"15_CR52","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/bjc.2017.305","volume":"117","author":"A Almaz\u00e1n-Moga","year":"2017","unstructured":"Almaz\u00e1n-Moga, A., Zarzosa, P., Molist, C., et al. (2017). Ligand-dependent hedgehog pathway activation in Rhabdomyosarcoma: The oncogenic role of the ligands. British Journal of Cancer, 117(9), 1314\u20131325.","journal-title":"British Journal of Cancer"},{"issue":"7","key":"15_CR53","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/jclinpath-2011-200071","volume":"64","author":"K Thway","year":"2011","unstructured":"Thway, K., Selfe, J., Missiaglia, E., et al. (2011). Glypican-3 is expressed in rhabdomyosarcomas but not adult spindle cell and pleomorphic sarcomas. Journal of Clinical Pathology, 64(7), 587\u2013591.","journal-title":"Journal of Clinical Pathology"},{"issue":"5","key":"15_CR54","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.devcel.2008.03.006","volume":"14","author":"MI Capurro","year":"2008","unstructured":"Capurro, M. I., Xu, P., Shi, W., et al. (2008). Glypican-3 inhibits hedgehog signaling during development by competing with patched for hedgehog binding. Developmental Cell, 14(5), 700\u2013711.","journal-title":"Developmental Cell"},{"issue":"5","key":"15_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126562","volume":"10","author":"M Takeuchi","year":"2015","unstructured":"Takeuchi, M., Higashino, A., Takeuchi, K., et al. (2015). Transcriptional dynamics of immortalized human mesenchymal stem cells during transformation. PLoS One, 10(5), e0126562.","journal-title":"PLoS One"},{"issue":"2","key":"15_CR56","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/ceo.12139","volume":"42","author":"WQ Tang","year":"2014","unstructured":"Tang, W. Q., Hei, Y., Kang, L., et al. (2014). Heparanase-1 and components of the hedgehog signalling pathway are increased in untreated alveolar orbital rhabdomyosarcoma. Clinical & Experimental Ophthalmology, 42(2), 182\u2013189.","journal-title":"Clinical & Experimental Ophthalmology"},{"issue":"2","key":"15_CR57","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3892\/etm.2010.189","volume":"2","author":"LD Ridgway","year":"2011","unstructured":"Ridgway, L. D., Wetzel, M. D., & Marchetti, D. (2011). Heparanase modulates Shh and Wnt3a signaling in human medulloblastoma cells. Experimental and Therapeutic Medicine, 2(2), 229\u2013238.","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"3","key":"15_CR58","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.path.2017.04.006","volume":"10","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y., & Rosenberg, A. E. (2017). Bone-forming tumors. Surgical Pathology Clinics, 10(3), 513\u2013535.","journal-title":"Surgical Pathology Clinics"},{"issue":"15","key":"15_CR59","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1242\/dev.136861","volume":"143","author":"KK Sivaraj","year":"2016","unstructured":"Sivaraj, K. K., & Adams, R. H. (2016). Blood vessel formation and function in bone. Development, 143(15), 2706\u20132715.","journal-title":"Development"},{"issue":"11","key":"15_CR60","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrc3838","volume":"14","author":"M Kansara","year":"2014","unstructured":"Kansara, M., Teng, M. W., Smyth, M. J., et al. (2014). Translational biology of osteosarcoma. Nature Reviews. Cancer, 14(11), 722\u2013735.","journal-title":"Nature Reviews. Cancer"},{"key":"15_CR61","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1146\/annurev.cellbio.042308.113308","volume":"25","author":"G Karsenty","year":"2009","unstructured":"Karsenty, G., Kronenberg, H. M., & Settembre, C. (2009). Genetic control of bone formation. Annual Review of Cell and Developmental Biology, 25, 629\u2013648.","journal-title":"Annual Review of Cell and Developmental Biology"},{"issue":"2","key":"15_CR62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/cbf.2939","volume":"31","author":"PP Dwivedi","year":"2013","unstructured":"Dwivedi, P. P., Lam, N., & Powell, B. C. (2013). Boning up on glypicans--opportunities for new insights into bone biology. Cell Biochemistry and Function, 31(2), 91\u2013114.","journal-title":"Cell Biochemistry and Function"},{"issue":"9","key":"15_CR63","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.biocel.2005.03.006","volume":"37","author":"SM Cool","year":"2005","unstructured":"Cool, S. M., & Nurcombe, V. (2005). The osteoblast-heparan sulfate axis: control of the bone cell lineage. The International Journal of Biochemistry & Cell Biology, 37(9), 1739\u20131745.","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"6","key":"15_CR64","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.2106\/00004623-200206000-00022","volume":"84-A","author":"JR Lieberman","year":"2002","unstructured":"Lieberman, J. R., Daluiski, A., & Einhorn, T. A. (2002). The role of growth factors in the repair of bone. Biology and clinical applications. The Journal of Bone and Joint Surgery. American Volume, 84-A(6), 1032\u20131044.","journal-title":"The Journal of Bone and Joint Surgery. American Volume"},{"key":"15_CR65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.matbio.2013.11.003","volume":"34","author":"K Jochmann","year":"2014","unstructured":"Jochmann, K., Bachvarova, V., & Vortkamp, A. (2014). Heparan sulfate as a regulator of endochondral ossification and osteochondroma development. Matrix Biology, 34, 55\u201363.","journal-title":"Matrix Biology"},{"issue":"5","key":"15_CR66","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10735-007-9123-4","volume":"38","author":"V Nurcombe","year":"2007","unstructured":"Nurcombe, V., Goh, F. J., Haupt, L. M., et al. (2007). Temporal and functional changes in glycosaminoglycan expression during osteogenesis. Journal of Molecular Histology, 38(5), 469\u2013481.","journal-title":"Journal of Molecular Histology"},{"issue":"22","key":"15_CR67","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/S0960-9822(00)80060-3","volume":"9","author":"SE Guimond","year":"1999","unstructured":"Guimond, S. E., & Turnbull, J. E. (1999). Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides. Current Biology, 9(22), 1343\u20131346.","journal-title":"Current Biology"},{"issue":"6","key":"15_CR68","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00418-003-0589-1","volume":"120","author":"M Saijo","year":"2003","unstructured":"Saijo, M., Kitazawa, R., Nakajima, M., et al. (2003). Heparanase mRNA expression during fracture repair in mice. Histochemistry and Cell Biology, 120(6), 493\u2013503.","journal-title":"Histochemistry and Cell Biology"},{"issue":"3","key":"15_CR69","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/jcp.20625","volume":"207","author":"V Kram","year":"2006","unstructured":"Kram, V., Zcharia, E., Yacoby-Zeevi, O., et al. (2006). Heparanase is expressed in osteoblastic cells and stimulates bone formation and bone mass. Journal of Cellular Physiology, 207(3), 784\u2013792.","journal-title":"Journal of Cellular Physiology"},{"key":"15_CR70","doi-asserted-by":"publisher","unstructured":"Aldi, S., Eriksson, L., Kronqvist, M., et al. (2019). Dual roles of heparanase in human carotid plaque calcification. Atherosclerosis. \nhttps:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.12.027\n\n.","DOI":"10.1016\/j.atherosclerosis.2018.12.027"},{"issue":"3","key":"15_CR71","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/jcp.21825","volume":"220","author":"LM Haupt","year":"2009","unstructured":"Haupt, L. M., Murali, S., Mun, F. K., et al. (2009). The heparan sulfate proteoglycan (HSPG) glypican-3 mediates commitment of MC3T3-E1 cells toward osteogenesis. Journal of Cellular Physiology, 220(3), 780\u2013791.","journal-title":"Journal of Cellular Physiology"},{"key":"15_CR72","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/bonekey.2015.33","volume":"4","author":"R Mansouri","year":"2015","unstructured":"Mansouri, R., Ha\u00ff, E., Marie, P. J., et al. (2015). Role of syndecan-2 in osteoblast biology and pathology. Bonekey Reports, 4, 666.","journal-title":"Bonekey Reports"},{"issue":"1","key":"15_CR73","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/jcb.22108","volume":"107","author":"NM Teplyuk","year":"2009","unstructured":"Teplyuk, N. M., Haupt, L. M., Ling, L., et al. (2009). The osteogenic transcription factor Runx2 regulates components of the fibroblast growth factor\/proteoglycan signaling axis in osteoblasts. Journal of Cellular Biochemistry, 107(1), 144\u2013154.","journal-title":"Journal of Cellular Biochemistry"},{"key":"15_CR74","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.gene.2006.04.028","volume":"379","author":"RA Jackson","year":"2006","unstructured":"Jackson, R. A., Nurcombe, V., & Cool, S. M. (2006). Coordinated fibroblast growth factor and heparan sulfate regulation of osteogenesis. Gene, 379, 79\u201391.","journal-title":"Gene"},{"issue":"8","key":"15_CR75","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1172\/JCI8641","volume":"105","author":"A Montero","year":"2000","unstructured":"Montero, A., Okada, Y., Tomita, M., et al. (2000). Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. The Journal of Clinical Investigation, 105(8), 1085\u20131093.","journal-title":"The Journal of Clinical Investigation"},{"issue":"14","key":"15_CR76","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1101\/gad.266551.115","volume":"29","author":"DM Ornitz","year":"2015","unstructured":"Ornitz, D. M., & Marie, P. J. (2015). Fibroblast growth factor signaling in skeletal development and disease. Genes & Development, 29(14), 1463\u20131486.","journal-title":"Genes & Development"},{"key":"15_CR77","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.biochi.2016.05.017","volume":"127","author":"VH Pomin","year":"2016","unstructured":"Pomin, V. H. (2016). Paradigms in the structural biology of the mitogenic ternary complex FGF:FGFR:Heparin. Biochimie, 127, 214\u2013226.","journal-title":"Biochimie"},{"issue":"1","key":"15_CR78","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/jcp.20813","volume":"210","author":"RA Jackson","year":"2007","unstructured":"Jackson, R. A., Murali, S., van Wijnen, A. J., et al. (2007). Heparan sulfate regulates the anabolic activity of MC3T3-E1 preosteoblast cells by induction of Runx2. Journal of Cellular Physiology, 210(1), 38\u201350.","journal-title":"Journal of Cellular Physiology"},{"issue":"4","key":"15_CR79","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.bone.2008.05.022","volume":"43","author":"AJ Brown","year":"2008","unstructured":"Brown, A. J., Alicknavitch, M., D\u2019Souza, S. S., et al. (2008). Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation. Bone, 43(4), 689\u2013699.","journal-title":"Bone"},{"issue":"6","key":"15_CR80","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3892\/etm.2013.1070","volume":"5","author":"Q Han","year":"2013","unstructured":"Han, Q., Liu, F., & Zhou, Y. (2013). Increased expression of heparanase in osteogenic differentiation of rat marrow stromal cells. Experimental and Therapeutic Medicine, 5(6), 1697\u20131700.","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"10","key":"15_CR81","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/jor.21138","volume":"28","author":"PN Smith","year":"2010","unstructured":"Smith, P. N., Freeman, C., Yu, D., et al. (2010). Heparanase in primary human osteoblasts. Journal of Orthopaedic Research, 28(10), 1315\u20131322.","journal-title":"Journal of Orthopaedic Research"},{"issue":"10","key":"15_CR82","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1093\/nar\/gkq030","volume":"38","author":"B Drobic","year":"2010","unstructured":"Drobic, B., P\u00e9rez-Cadah\u00eda, B., Yu, J., et al. (2010). Promoter chromatin remodeling of immediate-early genes is mediated through H3 phosphorylation at either serine 28 or 10 by the MSK1 multi-protein complex. Nucleic Acids Research, 38(10), 3196\u20133208.","journal-title":"Nucleic Acids Research"},{"key":"15_CR83","doi-asserted-by":"crossref","unstructured":"Gibor, G., Ilan, N., Journo, S., et al. Heparanase is expressed in adult human osteoarthritic cartilage and drives catabolic responses in primary chondrocytes. Osteoarthritis and Cartilage, 26(8), 1110\u20131117.","DOI":"10.1016\/j.joca.2018.05.013"},{"issue":"21","key":"15_CR84","doi-asserted-by":"publisher","first-page":"8329","DOI":"10.1158\/0008-5472.CAN-10-2179","volume":"70","author":"Y Yang","year":"2010","unstructured":"Yang, Y., Ren, Y., Ramani, V. C., et al. (2010). Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. Cancer Research, 70(21), 8329\u20138338.","journal-title":"Cancer Research"},{"issue":"3","key":"15_CR85","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ajpath.2018.11.011","volume":"189","author":"A Chanalaris","year":"2019","unstructured":"Chanalaris, A., Clarke, H., Guimond, S. E., et al. (2019). Heparan sulfate proteoglycan synthesis is dysregulated in human osteoarthritic cartilage. The American Journal of Pathology, 189(3), 632\u2013647.","journal-title":"The American Journal of Pathology"},{"key":"15_CR86","doi-asserted-by":"publisher","unstructured":"Chow, W. A. (2018). Chondrosarcoma: Biology, genetics, and epigenetics. F1000Res. \nhttps:\/\/doi.org\/10.12688\/f1000research.15953.1\n\n.","DOI":"10.12688\/f1000research.15953.1"},{"issue":"7","key":"15_CR87","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nrc2869","volume":"10","author":"JV Bov\u00e9e","year":"2010","unstructured":"Bov\u00e9e, J. V., Hogendoorn, P. C., Wunder, J. S., et al. (2010). Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nature Reviews. Cancer, 10(7), 481\u2013488.","journal-title":"Nature Reviews. Cancer"},{"key":"15_CR88","doi-asserted-by":"crossref","unstructured":"Polychronidou, G., Karavasilis, V., Pollack, S. M., et al. Novel therapeutic approaches in chondrosarcoma. Future Oncology, 13(7), 637\u2013648.","DOI":"10.2217\/fon-2016-0226"},{"key":"15_CR89","unstructured":"Sonne-Holm E, Wong C, Sonne-Holm S et al. Multiple cartilaginous exostoses and development of chondrosarcomas\u2013a systematic review. Danish Medical Journal 61(9):A4895."},{"issue":"8","key":"15_CR90","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00264-013-1906-5","volume":"37","author":"A Cuellar","year":"2013","unstructured":"Cuellar, A., & Reddi, A. H. (2013). Cell biology of osteochondromas: bone morphogenic protein signalling and heparan sulphates. International Orthopaedics, 37(8), 1591\u20131596.","journal-title":"International Orthopaedics"},{"issue":"12","key":"15_CR91","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/humu.21123","volume":"30","author":"I Jennes","year":"2009","unstructured":"Jennes, I., Pedrini, E., & eta l, Z. M. (2009). Multiple osteochondromas: Mutation update and description of the multiple osteochondromas mutation database (MOdb). Human Mutation, 30(12), 1620\u20131627.","journal-title":"Human Mutation"},{"issue":"3","key":"15_CR92","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s11914-017-0355-2","volume":"15","author":"M Pacifici","year":"2017","unstructured":"Pacifici, M. (2017). Hereditary Multiple Exostoses: New insights into pathogenesis, clinical complications, and potential treatments. Current Osteoporosis Reports, 15(3), 142\u2013152.","journal-title":"Current Osteoporosis Reports"},{"issue":"2","key":"15_CR93","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/514","volume":"19","author":"C McCormick","year":"1998","unstructured":"McCormick, C., Leduc, Y., Martindale, D., et al. (1998). The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nature Genetics, 19(2), 158\u2013161.","journal-title":"Nature Genetics"},{"issue":"4","key":"15_CR94","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1897-4287-2-4-161","volume":"2","author":"L Hameetman","year":"2004","unstructured":"Hameetman, L., Bov\u00e9e, J. V., Taminiau, A. H., et al. (2004). Multiple osteochondromas: Clinicopathological and genetic spectrum and suggestions for clinical management. Hereditary Cancer in Clinical Practice, 2(4), 161\u2013173.","journal-title":"Hereditary Cancer in Clinical Practice"},{"issue":"6","key":"15_CR95","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.devcel.2004.05.009","volume":"6","author":"L Koziel","year":"2004","unstructured":"Koziel, L., Kunath, M., Kelly, O. G., et al. (2004). Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. Developmental Cell, 6(6), 801\u2013813.","journal-title":"Developmental Cell"},{"key":"15_CR96","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.matbio.2017.12.011","volume":"71-72","author":"M Pacifici","year":"2018","unstructured":"Pacifici, M. (2018). The pathogenic roles of heparan sulfate deficiency in hereditary multiple exostoses. Matrix Biology, 71-72, 28\u201339.","journal-title":"Matrix Biology"},{"issue":"5","key":"15_CR97","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1073\/pnas.0910875107","volume":"107","author":"KB Jones","year":"2010","unstructured":"Jones, K. B., Piombo, V., Searby, C., et al. (2010). A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proceedings of the National Academy of Sciences of the United States of America, 107(5), 2054\u20132059.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"15_CR98","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/onc.2011.311","volume":"31","author":"CE Andrea de","year":"2012","unstructured":"de Andrea, C. E., Reijnders, C. M., Kroon, H. M., et al. (2012). Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT. Oncogene, 31(9), 1095\u20131104.","journal-title":"Oncogene"},{"issue":"2","key":"15_CR99","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/path.3003","volume":"226","author":"CE Andrea de","year":"2012","unstructured":"de Andrea, C. E., & Hogendoorn, P. C. (2012). Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter. The Journal of Pathology, 226(2), 219\u2013228.","journal-title":"The Journal of Pathology"},{"issue":"5","key":"15_CR100","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-2613.2008.00589.x","volume":"89","author":"M Trebicz-Geffen","year":"2008","unstructured":"Trebicz-Geffen, M., Robinson, D., Evron, Z., et al. (2008). The molecular and cellular basis of exostosis formation in hereditary multiple exostoses. International Journal of Experimental Pathology, 89(5), 321\u2013331.","journal-title":"International Journal of Experimental Pathology"},{"issue":"11","key":"15_CR101","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/jor.21162","volume":"28","author":"L Yang","year":"2010","unstructured":"Yang, L., Hui, W. S., Chan, W. C., et al. (2010). A splice-site mutation leads to haploinsufficiency of EXT2 mRNA for a dominant trait in a large family with multiple osteochondromas. Journal of Orthopaedic Research, 28(11), 1522\u20131530.","journal-title":"Journal of Orthopaedic Research"},{"issue":"6","key":"15_CR102","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.ajpath.2015.02.014","volume":"185","author":"J Huegel","year":"2015","unstructured":"Huegel, J., Enomoto-Iwamoto, M., Sgariglia, F., et al. (2015). Heparanase stimulates chondrogenesis and is up-regulated in human ectopic cartilage: A mechanism possibly involved in hereditary multiple exostoses. The American Journal of Pathology, 185(6), 1676\u20131685.","journal-title":"The American Journal of Pathology"},{"issue":"12","key":"15_CR103","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1073\/pnas.0705807105","volume":"105","author":"J Presto","year":"2008","unstructured":"Presto, J., Thuveson, M., Carlsson, P., et al. (2008). Heparan sulfate biosynthesis enzymes EXT1 and EXT2 affect NDST1 expression and heparan sulfate sulfation. Proceedings of the National Academy of Sciences of the United States of America, 105(12), 4751\u20134756.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"15_CR104","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.3390\/molecules23123277","volume":"23","author":"N Veraldi","year":"2018","unstructured":"Veraldi, N., Parra, A., Urso, E., et al. (2018). Structural Features of Heparan Sulfate from Multiple Osteochondromas and Chondrosarcomas. Molecules, 23, 3277.","journal-title":"Molecules"},{"issue":"2","key":"15_CR105","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jbiotec.2007.01.022","volume":"129","author":"WC Lamanna","year":"2007","unstructured":"Lamanna, W. C., Kalus, I., Padva, M., et al. (2007). The heparanome--the enigma of encoding and decoding heparan sulfate sulfation. Journal of Biotechnology, 129(2), 290\u2013307.","journal-title":"Journal of Biotechnology"},{"issue":"4","key":"15_CR106","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00428-012-1300-5","volume":"461","author":"CJ Waaijer","year":"2012","unstructured":"Waaijer, C. J., de Andrea, C. E., Hamilton, A., et al. (2012). Cartilage tumour progression is characterized by an increased expression of heparan sulphate 6O-sulphation-modifying enzymes. Virchows Archiv, 461(4), 475\u2013481.","journal-title":"Virchows Archiv"},{"issue":"3","key":"15_CR107","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2353\/ajpath.2009.080623","volume":"174","author":"YM Schrage","year":"2009","unstructured":"Schrage, Y. M., Hameetman, L., Szuhai, K., et al. (2009). Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma. The American Journal of Pathology, 174(3), 979\u2013988.","journal-title":"The American Journal of Pathology"},{"issue":"4","key":"15_CR108","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.ajpath.2012.12.036","volume":"182","author":"JG Oosterwijk van","year":"2013","unstructured":"van Oosterwijk, J. G., Meijer, D., van Ruler, M. A., et al. (2013). Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGF\u03b2 as potential targets. The American Journal of Pathology, 182(4), 1347\u20131356.","journal-title":"The American Journal of Pathology"},{"key":"15_CR109","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bone.2016.10.017","volume":"102","author":"K Rickel","year":"2017","unstructured":"Rickel, K., Fang, F., & Tao, J. (2017). Molecular genetics of osteosarcoma. Bone, 102, 69\u201379.","journal-title":"Bone"},{"issue":"8","key":"15_CR110","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.molmed.2017.06.004","volume":"23","author":"YH Lin","year":"2017","unstructured":"Lin, Y. H., Jewell, B. E., Gingold, J., et al. (2017). Osteosarcoma: Molecular pathogenesis and iPSC modeling. Trends in Molecular Medicine, 23(8), 737\u2013755.","journal-title":"Trends in Molecular Medicine"},{"key":"15_CR111","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jpedsurg.2005.12.001","volume":"41","author":"M Tataria","year":"2006","unstructured":"Tataria, M., Quarto, N., Longaker, M. T., et al. (2006). Absence of the p53 tumor suppressor gene promotes osteogenesis in mesenchymal stem cells. Journal of Pediatric Surgery, 41, 624\u2013632.","journal-title":"Journal of Pediatric Surgery"},{"issue":"2","key":"15_CR112","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.cell.2015.02.045","volume":"161","author":"DF Lee","year":"2015","unstructured":"Lee, D. F., Su, J., Kim, H. S., et al. (2015). Modeling familial cancer with induced pluripotent stem cells. Cell, 161(2), 240\u2013254.","journal-title":"Cell"},{"issue":"8","key":"15_CR113","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/jcb.24793","volume":"115","author":"JL Sottnik","year":"2014","unstructured":"Sottnik, J. L., Campbell, B., Mehra, R., et al. (2014). Osteocytes serve as a progenitor cell of osteosarcoma. Journal of Cellular Biochemistry, 115(8), 1420\u20131429.","journal-title":"Journal of Cellular Biochemistry"},{"issue":"8","key":"15_CR114","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1158\/0008-5472.CAN-06-4164","volume":"67","author":"A Orosco","year":"2007","unstructured":"Orosco, A., Fromigu\u00e9, O., Bazille, C., et al. (2007). Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma. Cancer Research, 67(8), 3708\u20133715.","journal-title":"Cancer Research"},{"issue":"4","key":"15_CR115","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/PAT.0b013e328353447b","volume":"44","author":"KY Na","year":"2012","unstructured":"Na, K. Y., Bacchini, P., Bertoni, F., et al. (2012). Syndecan-4 and fibronectin in osteosarcoma. Pathology, 44(4), 325\u2013330.","journal-title":"Pathology"},{"issue":"4","key":"15_CR116","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/0008-5472.CAN-08-2742","volume":"69","author":"BN Chau","year":"2009","unstructured":"Chau, B. N., Diaz, R. L., Saunders, M. A., et al. (2009). Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analyses. Cancer Research, 69(4), 1368\u20131374.","journal-title":"Cancer Research"},{"issue":"28","key":"15_CR117","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1038\/sj.onc.1209425","volume":"25","author":"L Baraz","year":"2006","unstructured":"Baraz, L., Haupt, Y., Elkin, M., et al. (2006). Tumor suppressor p53 regulates heparanase gene expression. Oncogene, 25(28), 3939\u20133947.","journal-title":"Oncogene"},{"issue":"1","key":"15_CR118","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4055\/jkoa.2006.41.1.43","volume":"41","author":"HS Kim","year":"2006","unstructured":"Kim, H. S., Kim, J. H., Oh, J. H., et al. (2006). Expression and clinical significance of heparanase in osteosarcoma. Journal of the Korean Orthopaedic Association, 41(1), 43\u201351.","journal-title":"Journal of the Korean Orthopaedic Association"},{"key":"15_CR119","doi-asserted-by":"crossref","unstructured":"Zeng, C., Ke, Z., Luo, C., et al. (2010). Heparanase participates in the growth and invasion of human U-2OS osteosarcoma cells and its close relationship with hypoxia-inducible factor-1\u03b1 in osteosarcoma. Neoplasms, 57(6).","DOI":"10.4149\/neo_2010_06_562"},{"issue":"3","key":"15_CR120","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s11596-011-0379-2","volume":"31","author":"L Fan","year":"2011","unstructured":"Fan, L., Wu, Q., Xing, X., et al. (2011). Targeted silencing of heparanase gene by small interfering RNA inhibits invasiveness and metastasis of osteosarcoma cells. Journal of Huazhong University of Science and Technology, 31(3), 348\u2013352.","journal-title":"Journal of Huazhong University of Science and Technology"},{"key":"15_CR121","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11010-012-1475-8","volume":"373","author":"Y Wang","year":"2013","unstructured":"Wang, Y., Yang, X. Y., Yamagata, S., et al. (2013). Involvement of Ext1 and heparanase in migration of mouse FBJ osteosarcoma cells. Molecular and Cellular Biochemistry, 373, 63\u201372.","journal-title":"Molecular and Cellular Biochemistry"},{"issue":"6","key":"15_CR122","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4155\/fmc-2016-0012","volume":"8","author":"S Rivara","year":"2016","unstructured":"Rivara, S., Milazzo, F. M., & Giannini, G. (2016). Heparanase: A rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Medicinal Chemistry, 8(6), 647\u2013680.","journal-title":"Future Medicinal Chemistry"},{"issue":"6","key":"15_CR123","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood-2007-04-082495","volume":"110","author":"Y Yang","year":"2007","unstructured":"Yang, Y., MacLeod, V., & al, D. Y. (2007). The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood, 110(6), 2041\u20132048.","journal-title":"Blood"},{"issue":"6","key":"15_CR124","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/1078-0432.CCR-10-2476","volume":"17","author":"JP Ritchie","year":"2011","unstructured":"Ritchie, J. P., Ramani, V. C., Ren, Y., et al. (2011). SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase\/syndecan-1 axis. Clinical Cancer Research, 17(6), 1382\u20131393.","journal-title":"Clinical Cancer Research"},{"key":"15_CR125","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/157496","volume":"2012","author":"S Manier","year":"2012","unstructured":"Manier, S., Sacco, A., Leleu, X., et al. (2012). Bone marrow microenvironment in multiple myeloma progression. Journal of Biomedicine & Biotechnology, 2012, 157496.","journal-title":"Journal of Biomedicine & Biotechnology"},{"key":"15_CR126","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fonc.2015.00279","volume":"5","author":"F Redini","year":"2015","unstructured":"Redini, F., & Heymann, D. (2015). Bone tumor environment as a potential therapeutic target in Ewing sarcoma. Frontiers in Oncology, 5, 279.","journal-title":"Frontiers in Oncology"},{"issue":"16","key":"15_CR127","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-09-2261","volume":"16","author":"HV Erkizan","year":"2010","unstructured":"Erkizan, H. V., Uversky, V. N., & Toretsky, J. A. (2010). Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing\u2019s sarcoma. Clinical Cancer Research, 16(16), 4077\u20134083.","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"15_CR128","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/sj.bjc.6605775","volume":"103","author":"S Kamura","year":"2010","unstructured":"Kamura, S., Matsumoto, Y., Fukushi, J. I., et al. (2010). Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing\u2019s sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway. British Journal of Cancer, 103(3), 370\u2013381.","journal-title":"British Journal of Cancer"},{"issue":"18","key":"15_CR129","doi-asserted-by":"publisher","first-page":"13326","DOI":"10.1074\/jbc.M611259200","volume":"282","author":"Y Yang","year":"2007","unstructured":"Yang, Y., Macleod, V., Miao, H. Q., et al. (2007). Heparanase enhances syndecan-1 shedding: A novel mechanism for stimulation of tumor growth and metastasis. The Journal of Biological Chemistry, 282(18), 13326\u201313333.","journal-title":"The Journal of Biological Chemistry"},{"issue":"30","key":"15_CR130","doi-asserted-by":"publisher","first-page":"47848","DOI":"10.18632\/oncotarget.10292","volume":"7","author":"G Cassinelli","year":"2016","unstructured":"Cassinelli, G., Favini, E., Dal Bo, L., et al. (2016). Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases. Oncotarget, 7(30), 47848\u201347863.","journal-title":"Oncotarget"},{"issue":"13","key":"15_CR131","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1096\/fj.07-8450com","volume":"21","author":"N Hostettler","year":"2007","unstructured":"Hostettler, N., Naggi, A., Torri, G., et al. (2007). P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. The FASEB Journal, 21(13), 3562\u20133572.","journal-title":"The FASEB Journal"},{"issue":"1","key":"15_CR132","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/ng0197-95","volume":"15","author":"MP Simon","year":"1997","unstructured":"Simon, M. P., Pedeutour, F., Sirvent, N., et al. (1997). Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nature Genetics, 15(1), 95\u201398.","journal-title":"Nature Genetics"},{"issue":"15","key":"15_CR133","first-page":"3588","volume":"59","author":"Y Xie","year":"1999","unstructured":"Xie, Y., Skytting, B., Nilsson, G., et al. (1999). Expression of insulin-like growth factor-1 receptor in synovial sarcoma: Association with an aggressive phenotype. Cancer Research, 59(15), 3588\u20133591.","journal-title":"Cancer Research"},{"issue":"7","key":"15_CR134","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/sj.onc.1209143","volume":"25","author":"Y Sun","year":"2006","unstructured":"Sun, Y., Gao, D., Liu, Y., et al. (2006). IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene, 25(7), 1042\u20131052.","journal-title":"Oncogene"},{"issue":"2","key":"15_CR135","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.canlet.2010.05.016","volume":"297","author":"MS Basappa","year":"2010","unstructured":"Basappa, M. S., Kavitha, C. V., et al. (2010). A small oxazine compound as an anti-tumor agent: A novel pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-\u03b1. Cancer Letters, 297(2), 231\u2013243.","journal-title":"Cancer Letters"},{"issue":"11","key":"15_CR136","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.3390\/molecules23112915","volume":"23","author":"C Lanzi","year":"2018","unstructured":"Lanzi, C., & Cassinelli, G. (2018). Heparan sulfate mimetics in cancer therapy: The challenge to define structural determinants and the relevance of targets for optimal activity. Molecules, 23(11), 2915.","journal-title":"Molecules"},{"issue":"15","key":"15_CR137","doi-asserted-by":"publisher","first-page":"6918","DOI":"10.1021\/acs.jmedchem.8b00908","volume":"61","author":"VN Madia","year":"2018","unstructured":"Madia, V. N., Messore, A., Pescatori, L., et al. (2018). Novel Benzazole derivatives endowed with potent Antiheparanase activity. Journal of Medicinal Chemistry, 61(15), 6918\u20136936.","journal-title":"Journal of Medicinal Chemistry"},{"issue":"23","key":"15_CR138","doi-asserted-by":"publisher","first-page":"10834","DOI":"10.1021\/acs.jmedchem.8b01497","volume":"61","author":"A Messore","year":"2018","unstructured":"Messore, A., Madia, V. N., Pescatori, L., et al. (2018). Novel symmetrical Benzazolyl derivatives endowed with potent anti-Heparanase activity. Journal of Medicinal Chemistry, 61(23), 10834\u201310859.","journal-title":"Journal of Medicinal Chemistry"}],"container-title":["Advances in Experimental Medicine and Biology","Heparanase"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-34521-1_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T08:08:55Z","timestamp":1586419735000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-34521-1_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030345204","9783030345211"],"references-count":138,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-34521-1_15","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"10 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}